Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up
AC

ACAD

Market Closed

ACADIA Pharmaceuticals Inc.

NASDAQHealthcareBiotechnology
US
798 employees
CEO: Catherine E. Owen Adams
Founded: 2004
$28.45
+$0.00(+NaN%)
Market Cap
4.87B
Beta
0.80
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: ACAD trades 16.3% above a high-confidence fair value of $24.11, with mixed valuation signals: negative DCF but strong P/E and analyst targets. Financial health is robust, scoring 4.60/5, indicating low operational risk. Monte Carlo analysis shows zero downside scenarios below current price, suggesting limited risk at current levels.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore ACAD

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

ACAD in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Biotechnology

Browse industry stocks →

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms